Evidence map›Paper›PMID 29716959›Full record

ReviewJournal of lipid research2018

The phospholipase A

Aron B Fisher

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of lipid research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 115 citations in OpenAlex.

  1. Phospholipases: Where Do We Stand?Methods in molecular biology (Clifton, N.J.) · 2027
    Review
  2. Review
  3. Loss of Peroxiredoxin 6 Drives Age-Related Klf9/NF-Antioxidants (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. In defence of ferroptosis.Signal transduction and targeted therapy · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Aron B FisherInstitute for Environmental Medicine of the Department of Physiology, University of Pennsylvania, Philadelphia, PA 19103 ABF@UPenn.edu.
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Trevor M Penning · 2006 to 2026
$35.3M
Role of Peroxiredoxin 6 in the Repair of Peroxidized Cell MembranesR01HL102016 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2010 to 2018
$4.6M
NHLBI NIH HHS R01 HL102016NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

Peroxiredoxin 6 (Prdx6) is a Ca

Indexed as

AnimalsDiseaseHumansPeroxiredoxin VIPeroxiredoxin VIaiPLA2antioxidantslipid peroxidationlysosomal PLA2moonlighting proteinphospholipid/metabolismphospholipid remodelingphospholipids/phosphatidylcholinephospholipid turnoverprotein phosphorylation

Identifiers

PMID29716959
PMCPMC6027911
OpenAlexW2800057211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.